- Reuters•11 minutes ago
Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, did not surpass Takeda Pharmaceutical Co Ltd's Velcade in a head-to-head late-stage study in previously untreated patients. The U.S. Food and Drug Administration has already approved Kyprolis for patients with relapsed or refractory multiple myeloma who have previously undergone one or more treatments. The latest study tested a regimen of Kyprolis against Velcade in patients who also received the chemothereutic agent melphalan and the immunosuppressant prednisone, and were deemed ineligible for stem-cell transplants.
- 24/7 Wall St.•1 hour ago
The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||169.76 x 200|
|Ask||170.00 x 100|
|Day's Range||172.83 - 174.42|
|52wk Range||131.43 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.76|
|Avg Vol (3m)||2,847,721|
|Dividend & Yield||4.00 (2.29%)|